Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash & Current Investments (2024 - 2025)

Historic Cash & Current Investments for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $65.6 million.

  • Prelude Therapeutics' Cash & Current Investments fell 5837.83% to $65.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year decrease of 5837.83%. This contributed to the annual value of $137.7 million for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Cash & Current Investments stood at $65.6 million for Q3 2025, which was down 5837.83% from $124.8 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Cash & Current Investments registered a high of $206.0 million during Q1 2024, and its lowest value of $65.6 million during Q3 2025.